Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.

Conclusion: Apatinib is actively used in treating patients with recurrent AM. A randomized trial and phase II clinical trial of this inhibitor should be performed to further evaluate its efficacy in treating malignant meningioma.
PMID: 32212907 [PubMed - as supplied by publisher]

Source: Cancer Biology and Therapy - March 24, 2020 Category: Cancer & Oncology Authors: Wang Y, Li W, Jing N, Meng X, Zhou S, Zhu Y, Xu J, Tao R Tags: Cancer Biol Ther Source Type: research